{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:44Z","timestamp":1781643524938,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Lupus nephritis (LN) is a major contributor to morbidity and death in systemic lupus erythematosus (SLE), particularly in children. CD163 is a macrophage- and monocyte-specific receptor that can be cleaved and released as soluble CD163 (sCD163). Both circulating and urinary sCD163 reflect macrophage activation and are elevated in inflammatory and autoimmune conditions, highlighting their potential as biomarkers of renal inflammation. There is unmet need to develop a set of biomarkers that can accurately reflect disease activity and prognosis and differentiate active from non-active cases.\n                      <jats:bold>In this context<\/jats:bold>\n                      , we aimed to evaluate serum and urinary sCD163 levels in children with active LN and to examine their association with established clinical and laboratory markers of SLE activity. Additionally, we explored differences in sCD163 levels between patients with renal versus extrarenal SLE activity and between inflammatory LN and non-inflammatory chronic kidney disease (CKD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 60 pediatric participants in four qual groups, Group 1: patients with active LN, group 2: SLE non-LN with active extrarenal disease, determined by SLEDAI and BILAG-2004 indices, group 3: non-lupus CKD, and group 4: healthy matched controls. Serum and urine levels of sCD163 were determined in all participants by ELISA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum and urinary sCD163 levels differed significantly among the study groups, with the highest levels in active LN. Patients with active renal BILAG scores A or B had significantly higher sCD163 levels than those with BILAG E, while no significant differences across histopathological classes. Serum sCD163 correlated negatively with eGFR and positively with proteinuria, whereas urinary sCD163 correlated positively with SLEDAI, proteinuria, and prednisolone dose. Both serum and urinary sCD163 distinguished renal from extrarenal SLE activity and LN from non-inflammatory CKD, with complete separation between groups (AUC\u2009=\u20091). No significant correlation was found between serum and urinary sCD163.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both sCD163 levels were associated with LN activity and differed from levels in extrarenal SLE and non-inflammatory CKD, suggesting that sCD163 may serve as a potential biomarker of kidney inflammation in pediatric SLLE patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-026-01201-y","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:18:37Z","timestamp":1774343917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum and urinary soluble CD163 in children with active lupus nephritis"],"prefix":"10.1186","volume":"24","author":[{"given":"Rasha Hassan El","family":"Owaidy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magid Ashraf","family":"Ibraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen Hasan","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Adel","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara I.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4684-229X","authenticated-orcid":false,"given":"Dina E.","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"19","key":"1201_CR1","doi-asserted-by":"publisher","first-page":"14526","DOI":"10.3390\/ijms241914526","volume":"24","author":"Y Renaudineau","year":"2023","unstructured":"Renaudineau Y, Brooks W, Belliere J. Lupus Nephritis Risk Factors and Biomarkers: An Update. Int J Mol Sci. 2023;24(19):14526. https:\/\/doi.org\/10.3390\/ijms241914526. PMID: 37833974; PMCID: PMC10572905.","journal-title":"Int J Mol Sci"},{"issue":"28","key":"1201_CR2","doi-asserted-by":"publisher","first-page":"e16420","DOI":"10.1097\/MD.0000000000016420","volume":"98","author":"HS Choi","year":"2019","unstructured":"Choi HS, Han KD, Jung JH, Kim CS, Bae EH, Ma SK, Kim SW. The risk of end-stage kidney disease in systemic lupus erythematosus: A nationwide population-based study in Korea. Med (Baltim). 2019;98(28):e16420. https:\/\/doi.org\/10.1097\/MD.0000000000016420. PMID: 31305460; PMCID: PMC6641670.","journal-title":"Med (Baltim)"},{"issue":"12","key":"1201_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2215\/CJN.04830421","volume":"16","author":"G Moroni","year":"2021","unstructured":"Moroni G, Frontini G, Ponticelli C. When and How Is It Possible to Stop Therapy in Patients with Lupus Nephritis: A Narrative Review. Clin J Am Soc Nephrol. 2021;16(12):1909\u201317. https:\/\/doi.org\/10.2215\/CJN.04830421. Epub 2021 Jun 23. PMID: 34162696; PMCID: PMC8729481.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1201_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1159\/000517852","volume":"52","author":"M Radin","year":"2021","unstructured":"Radin M, Miraglia P, Barinotti A, Fenoglio R, Roccatello D, Sciascia S. Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review. Am J Nephrol. 2021;52(7):559\u201371. Epub 2021 Aug 13. PMID: 34515043.","journal-title":"Am J Nephrol"},{"issue":"Suppl5","key":"1201_CR5","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","volume":"59","author":"M Gasparotto","year":"2020","unstructured":"Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(Suppl5):v39\u201351. https:\/\/doi.org\/10.1093\/rheumatology\/keaa381. PMID: 33280015; PMCID: PMC7751166.","journal-title":"Rheumatology (Oxford)"},{"issue":"22","key":"1201_CR6","doi-asserted-by":"publisher","first-page":"12123","DOI":"10.3390\/ijms222212123","volume":"22","author":"N Chebotareva","year":"2021","unstructured":"Chebotareva N, Vinogradov A, McDonnell V, Zakharova NV, Indeykina MI, Moiseev S, Nikolaev EN, Kononikhin AS. Urinary Protein and Peptide Markers in Chronic Kidney Disease. Int J Mol Sci. 2021;22(22):12123. https:\/\/doi.org\/10.3390\/ijms222212123. PMID: 34830001; PMCID: PMC8625140.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1201_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/biom11070928","volume":"11","author":"H Yu","year":"2021","unstructured":"Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021;11(7):928. https:\/\/doi.org\/10.3390\/biom11070928. PMID: 34206696; PMCID: PMC8301935.","journal-title":"Biomolecules"},{"issue":"16","key":"1201_CR8","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.3390\/ijms21165925","volume":"21","author":"D Krijgsman","year":"2020","unstructured":"Krijgsman D, De Vries NL, Andersen MN, Skovbo A, Tollenaar RAEM, M\u00f8ller HJ, Hokland M, Kuppen PJK. CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood. Int J Mol Sci. 2020;21(16):5925. https:\/\/doi.org\/10.3390\/ijms21165925. PMID: 32824692; PMCID: PMC7460610.","journal-title":"Int J Mol Sci"},{"key":"1201_CR9","doi-asserted-by":"publisher","unstructured":"M\u00f8ller HJ. Soluble CD163., Scand. J Clin Lab Invest. 2012;72(1):1\u201313. https:\/\/doi.org\/10.3109\/00365513.2011.626868. Epub 2011 Nov 7. PMID: 22060747.","DOI":"10.3109\/00365513.2011.626868"},{"key":"1201_CR10","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly VP, Wong L, Kennedy C, Elliot LA, O\u2019Meachair S, Coughlan AM, O\u2019Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P, Buckley C, O\u2019Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O\u2019Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA. Urinary Soluble CD163 in Active Renal Vasculitis. J Am Soc Nephrol. 2016;27(9):2906-16. doi: 10.1681\/ASN.2015050511. Epub 2016 Mar 3. Erratum in: J Am Soc Nephrol. 2018;29(8):2255. PMID: 26940094; PMCID: PMC5004645.","DOI":"10.1681\/ASN.2015050511"},{"key":"1201_CR11","doi-asserted-by":"publisher","unstructured":"Yee C-S, Farewell V, Isenberg DA, Griffiths B, Teh L-S, Ian N, Bruce Y, Ahmad A, Rahman A, Prabu M, Akil N, McHugh C, Edwards, David D\u2019, Khamashta P, Maddison C, Gordon. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity, Rheumatology, Volume 48, Issue 6, June 2009, Pages 691\u2013695. https:\/\/doi.org\/10.1093\/rheumatology\/kep064","DOI":"10.1093\/rheumatology\/kep064"},{"key":"1201_CR12","doi-asserted-by":"publisher","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630\u2009\u2013\u200940. https:\/\/doi.org\/10.1002\/art.1780350606. PMID: 1599520.","DOI":"10.1002\/art.1780350606"},{"key":"1201_CR13","doi-asserted-by":"publisher","unstructured":"Markowitz GS, D\u2019Agati VD. The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007;71(6):491-5. https:\/\/doi.org\/10.1038\/sj.ki.5002118. Epub 2007 Jan 31. PMID: 17264872.","DOI":"10.1038\/sj.ki.5002118"},{"key":"1201_CR14","doi-asserted-by":"crossref","unstructured":"Pinheiro SVB, Dias RF, Fabiano RCG, Araujo SA, Silva ACSE. Pediatric lupus nephritis. J Bras Nefrol. 2019 Apr-Jun;41(2):252\u201365. Epub 2018 Nov 14. PMID: 30465590; PMCID: PMC6699445. doi: 10.1590\/2175-8239-JBN-2018-0097.","DOI":"10.1590\/2175-8239-jbn-2018-0097"},{"issue":"4","key":"1201_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1684\/ecn.2021.0471","volume":"32","author":"SI Taha","year":"2021","unstructured":"Taha SI, Samaan SF, Ibrahim RA, El-Sehsah EM, Youssef MK. Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity? Eur Cytokine Netw. 2021;32(4):83\u20138. https:\/\/doi.org\/10.1684\/ecn.2021.0471. PMID: 35118946; PMCID: PMC8831681.","journal-title":"Eur Cytokine Netw"},{"issue":"11","key":"1201_CR16","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832\u201343. https:\/\/doi.org\/10.2215\/CJN.01640309. Epub 2009 Oct 9. PMID: 19820136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1201_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00296-018-4120-3","volume":"39","author":"S Bhattacharya","year":"2019","unstructured":"Bhattacharya S, Aggarwal A. M2 macrophages and their role in rheumatic diseases. Rheumatol Int. 2019;39(5):769\u201380. https:\/\/doi.org\/10.1007\/s00296-018-4120-3. Epub 2018 Aug 9. PMID: 30094684.","journal-title":"Rheumatol Int"},{"issue":"1","key":"1201_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13075-015-0600-y","volume":"17","author":"K Kopetschke","year":"2015","unstructured":"Kopetschke K, Klocke J, Grie\u00dfbach AS, Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P, Riemekasten G. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Res Ther. 2015;17(1):94. https:\/\/doi.org\/10.1186\/s13075-015-0600-y. PMID: 25890061; PMCID: PMC4412098.","journal-title":"Arthritis Res Ther"},{"key":"1201_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-016-0989-y","volume":"18","author":"G Olmes","year":"2016","unstructured":"Olmes G, B\u00fcttner-Herold M, Ferrazzi F, Distel L, Amann K, Daniel C. CD163\u2009+\u2009M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res Ther. 2016;18:90. https:\/\/doi.org\/10.1186\/s13075-016-0989-y. PMID: 27091114; PMCID: PMC4835936.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1201_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.prp.2017.04.011","volume":"213","author":"J Li","year":"2017","unstructured":"Li J, Yu YF, Liu CH, Wang CM. Significance of M2 macrophages in glomerulonephritis with crescents. Pathol Res Pract. 2017;213(9):1215\u201320. https:\/\/doi.org\/10.1016\/j.prp.2017.04.011. Epub 2017 Apr 20. PMID: 28554749.","journal-title":"Pathol Res Pract"},{"issue":"7","key":"1201_CR21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall\u2019Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. Accelerating Medicines Partnership in SLE network. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902\u201314. https:\/\/doi.org\/10.1038\/s41590-019-0398-x. Epub 2019 Jun 17. Erratum in: Nat Immunol. 2019;: PMID: 31209404; PMCID: PMC6726437.","journal-title":"Nat Immunol"},{"issue":"11","key":"1201_CR22","doi-asserted-by":"publisher","first-page":"300060521104996","DOI":"10.1177\/03000605211049963","volume":"49","author":"G Yang","year":"2021","unstructured":"Yang G, Guo N, Yin J, Wu J. Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J Int Med Res. 2021;49(11):3000605211049963. PMID: 34755559; PMCID: PMC8586176.","journal-title":"J Int Med Res"},{"key":"1201_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3389\/fimmu.2020.00671","volume":"11","author":"T Zhang","year":"2020","unstructured":"Zhang T, Li H, Vanarsa K, Gidley G, Mok CC, Petri M, Saxena R, Mohan C. Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. Front Immunol. 2020;11:671. PMID: 32351512; PMCID: PMC7174755.","journal-title":"Front Immunol"},{"issue":"3","key":"1201_CR24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10067-020-05343-6","volume":"40","author":"R Gupta","year":"2021","unstructured":"Gupta R, Yadav A, Aggarwal A. Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis. Clin Rheumatol. 2021;40(3):941\u20138. https:\/\/doi.org\/10.1007\/s10067-020-05343-6. Epub 2020 Aug 18. PMID: 32809146.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1201_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejr.2021.10.003","volume":"44","author":"NM Gamal","year":"2022","unstructured":"Gamal NM, Badawy ER, Talaat EA, Ibrahim HM, Abd Elsamea MH. Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients. Egypt Rheumatol. 2022;44(2):151\u20137. https:\/\/doi.org\/10.1016\/j.ejr.2021.10.003.","journal-title":"Egypt Rheumatol"},{"key":"1201_CR26","doi-asserted-by":"crossref","unstructured":"Nishino A, Katsumata Y, Kawasumi H, Hirahara S, Kawaguchi Y, Yamanaka H. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus. Lupus. 2019;28(8):986\u2013994. doi: 10.1177\/0961203319860201. PMID: 31246559.","DOI":"10.1177\/0961203319860201"},{"key":"1201_CR27","doi-asserted-by":"crossref","unstructured":"Huang YJ, Lin CH, Yang HY, Luo SF, Kuo CF. Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis. Front Immunol. 2022; 13:935700. doi: 10.3389\/fimmu.2022.935700. Erratum in: Front Immunol. 2022; 13:1003761. PMID: 35911758; PMCID: PMC9329951.","DOI":"10.3389\/fimmu.2022.935700"},{"key":"1201_CR28","doi-asserted-by":"publisher","unstructured":"Plevriti A, Lamprou M, Mourkogianni E, Skoulas N, Giannakopoulou M, Sajib MS, Wang Z, Mattheolabakis G, Chatzigeorgiou A, Marazioti A, Mikelis CM. The Role of Soluble CD163 (sCD163) in Human Physiology and Pathophysiology. Cells. 2024;13(20):1679. Published 2024 Oct 11. https:\/\/doi.org\/10.3390\/cells13201679","DOI":"10.3390\/cells13201679"},{"issue":"6","key":"1201_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1681\/ASN.2019121285","volume":"31","author":"JM Mejia-Vilet","year":"2020","unstructured":"Mejia-Vilet JM, Zhang XL, Cruz C, Cano-Verduzco ML, Shapiro JP, Nagaraja HN, Morales-Buenrostro LE, Rovin BH. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. J Am Soc Nephrol. 2020;31(6):1335\u201347. Epub 2020 Apr 16. PMID: 32300067; PMCID: PMC7269356.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1201_CR30","doi-asserted-by":"publisher","first-page":"R212","DOI":"10.1186\/ar4407","volume":"15","author":"G Zizzo","year":"2013","unstructured":"Zizzo G, Guerrieri J, Dittman LM, Merrill JT, Cohen PL. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes\/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther. 2013;15(6):R212. https:\/\/doi.org\/10.1186\/ar4407. PMID: 24325951; PMCID: PMC3978923.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1201_CR31","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/rheumatology\/keac465","volume":"62","author":"H Inthavong","year":"2023","unstructured":"Inthavong H, Vanarsa K, Castillo J, Hicks MJ, Mohan C, Wenderfer SE. Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis. Rheumatology (Oxford). 2023;62(3):1335\u201342. https:\/\/doi.org\/10.1093\/rheumatology\/keac465. PMID: 35961024; PMCID: PMC9977135.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1201_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12974-018-1383-2","volume":"16","author":"Peruzzaro","year":"2019","unstructured":"Peruzzaro ST, Andrews MMM, Al-Gharaibeh A, Pupiec O, Resk M, Story D, Maiti P, Rossignol J, Dunbar GL. Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury. J Neuroinflammation. 2019;16(1):2. https:\/\/doi.org\/10.1186\/s12974-018-1383-2. Erratum in: J Neuroinflammation. 2022;19(1):15. PMID: 30611291; PMCID: PMC6320578.","journal-title":"J Neuroinflammation"},{"key":"1201_CR33","doi-asserted-by":"publisher","unstructured":"Dekkema GJ, Abdulahad WH, Bijma T, Moran SM, Ryan L, Little MA, Stegeman CA, Heeringa P, Sanders JF. Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study. Nephrol Dial Transplant. 2019;34(2):234\u2013242. https:\/\/doi.org\/10.1093\/ndt\/gfy018. PMID: 29506265.","DOI":"10.1093\/ndt\/gfy018"},{"key":"1201_CR34","doi-asserted-by":"publisher","first-page":"100244","DOI":"10.1016\/j.jtauto.2024.100244","volume":"9","author":"Y Renaudineau","year":"2024","unstructured":"Renaudineau Y, Chauveau D, Faguer S, Huart A, Ribes D, Pugnet G, Sailler L, Jamme T, Treiner E, Fortenfant F, Bost C, Carl\u00e9 C, Belliere J. Urinary soluble CD163 is useful as liquid biopsy marker in lupus nephritis at both diagnosis and follow-up to predict impending flares. J Transl Autoimmun. 2024;9:100244. https:\/\/doi.org\/10.1016\/j.jtauto.2024.100244. PMID: 39021518; PMCID: PMC11253685.","journal-title":"J Transl Autoimmun"},{"key":"1201_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton (FL): CRC; 1993. pp. 178\u2013201."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01201-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:45:38Z","timestamp":1781642738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01201-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01201-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was carried out after approval by the Research Ethics Committee (REC) of the Ain Shams University Faculty of Medicine (approval number: FMASU MS 758\/2021). A written informed consent in simple Arabic language was obtained from all the participants and from the parents\/legal guardians of participants aged 16 years and below, prior to enrollment in the study. All data were kept private and utilized exclusively for research in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}